Pharma giant halts Excedrin products due to ingredient inconsistencies
The company says it ceased production and distribution for Excedrin Extra Strength and Excedrin Migraine products
Pharmaceutical giant GlaxoSmithKline temporarily discontinued two types of a popular medication used to treat headaches and migraines as a "precautionary measure."
The company says it ceased the nationwide production and distribution of its Excedrin Extra Strength and Excedrin Migraine products after inconsistencies with ingredients were discovered during routine checks, according to a GlaxoSmithKline spokesperson.
"Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs," the spokesperson told FOX Business Wednesday.
CALIFORNIA COULD LIST COMMON PAINKILLER AS CARCINOGEN
The company does not believe the medication poses a safety risk to consumers but has "voluntarily implemented a temporary discontinuation" as a safety measure.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| GSK | GSK PLC | 33.69 | +0.33 | +0.99% |
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The company says this is a "short term" issue and expects production to begin "shortly."
Meanwhile, other Excedrin products are still available along with other pain-relieving drugs, although the dosages may differ, the company says.
Consumers are urged to consult with their pharmacist for the most suitable alternative product until the company resumes production.
CLICK HERE TO READ MORE ON FOX BUSINESS